Evidence map›Paper›PMID 34584551›Full record

ReviewExperimental and therapeutic medicine2021

Current research developments of patient-derived tumour xenograft models (Review).

Zhenyu Yin, Ewetse Paul Maswikiti, Qian Liu, Yuping Bai, Xiaomei Li, Wenbo Qi, Le Liu, Yanling Ma, Hao Chen

Open access · diamondAbstract readReview
In one paragraph

Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zhenyu YinThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Ewetse Paul MaswikitiThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Qian LiuThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Yuping BaiThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Xiaomei LiThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Wenbo QiThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Le LiuThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Yanling MaThe Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Hao ChenDepartment of Oncology, Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Lanzhou University Second Hospital · CNLanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient-derived tumor xenograft (PDTX) models are established by transferring patient tumors into immunodeficient mice. In these murine models, the characteristics of the primary tumor are retained, including the microenvironment of tumor cell growth and histopathology. Due to this, it has become the most reliable

Indexed as

patient-derived tumor xenograftprecision medicinetumorsxenograft

Identifiers

PMID34584551
PMCPMC8422395
OpenAlexW3193838941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.